Lantheus (NASDAQ:LNTH) Releases Quarterly Earnings Results, Beats Estimates By $0.25 EPS
Lantheus (NASDAQ:LNTH) Releases Quarterly Earnings Results, Beats Estimates By $0.25 EPS
Lantheus (NASDAQ:LNTH – Get Rating) released its quarterly earnings results on Thursday. The medical equipment provider reported $0.89 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.25, Briefing.com reports. Lantheus had a return on equity of 28.88% and a net margin of 4.88%. The company had revenue of $223.80 million during the quarter, compared to analysts' expectations of $204.51 million. During the same quarter in the prior year, the business posted $0.11 earnings per share. The company's revenue for the quarter was up 121.4% compared to the same quarter last year. Lantheus updated its FY 2022 guidance to $3.50-$3.60 EPS and its Q3 2022 guidance to $0.80-$0.85 EPS.
蘭修斯(納斯達克:LNTH-GET評級)週四發佈了季度收益業績。據Briefing.com報道,這家醫療設備提供商公佈本季度每股收益(EPS)為0.89美元,比普遍預期的0.64美元高出0.25美元。蘭修斯的股本回報率為28.88%,淨利潤率為4.88%。該公司本季度營收為2.238億美元,高於分析師預期的2.0451億美元。在去年同一季度,該業務公佈的每股收益為0.11美元。該公司本季度的收入與去年同期相比增長了121.4%。Lantheus將其2022財年每股收益指引更新為3.50-3.60美元,將2022年第三季度每股收益指引更新為0.80-0.85美元。
Lantheus Price Performance
蘭修斯性價比
Shares of Lantheus stock traded up $7.33 during trading on Friday, hitting $78.57. The stock had a trading volume of 1,703,905 shares, compared to its average volume of 1,357,643. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.85 and a quick ratio of 1.64. The firm has a market cap of $5.39 billion, a P/E ratio of 182.72 and a beta of 0.79. The business has a fifty day moving average of $67.85 and a two-hundred day moving average of $55.77. Lantheus has a fifty-two week low of $22.20 and a fifty-two week high of $81.43.
在週五的交易中,Lantheus的股價上漲了7.33美元,達到78.57美元。該股成交量為1,703,905股,而其平均成交量為1,357,643股。該公司的債務權益比為0.27,流動比率為1.85,速動比率為1.64。該公司的市值為53.9億美元,市盈率為182.72,貝塔係數為0.79.該業務的50日移動均線切入位在67.85美元,200日移動均線切入位在55.77美元。蘭修斯的52周低點為22.20美元,52周高點為81.43美元。
Analyst Upgrades and Downgrades
分析師升級和下調評級
Several research firms have recently issued reports on LNTH. Truist Financial increased their price target on Lantheus from $77.00 to $94.00 in a research note on Monday, May 2nd. B. Riley started coverage on Lantheus in a research note on Monday, May 9th. They issued a "buy" rating and a $91.00 price target for the company. Finally, SVB Leerink upped their price objective on Lantheus from $100.00 to $110.00 and gave the company an "outperform" rating in a report on Friday.
幾家研究公司最近發佈了關於LNTH的報告。Truist Financial在5月2日星期一的一份研究報告中將其對Lantheus的目標價從77.00美元上調至94.00美元。B.萊利在5月9日星期一的一份研究報告中開始了對蘭修斯的報道。他們對該公司的評級為買入,目標價為91.00美元。最後,SVB Leerink在上週五的一份報告中將蘭修斯的目標價從100.00美元上調至110.00美元,並給予該公司“跑贏大盤”的評級。
Insider Activity
內幕活動
Institutional Investors Weigh In On Lantheus
機構投資者看好蘭修斯
Several hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. raised its position in Lantheus by 32.9% during the first quarter. Vanguard Group Inc. now owns 5,742,083 shares of the medical equipment provider's stock valued at $317,595,000 after buying an additional 1,422,269 shares during the period. Bank of New York Mellon Corp raised its position in Lantheus by 2.7% during the first quarter. Bank of New York Mellon Corp now owns 629,033 shares of the medical equipment provider's stock valued at $34,791,000 after buying an additional 16,422 shares during the period. Invesco Ltd. raised its position in Lantheus by 1.3% during the first quarter. Invesco Ltd. now owns 522,633 shares of the medical equipment provider's stock valued at $28,908,000 after buying an additional 6,706 shares during the period. Charles Schwab Investment Management Inc. raised its position in Lantheus by 9.2% during the first quarter. Charles Schwab Investment Management Inc. now owns 522,322 shares of the medical equipment provider's stock valued at $28,890,000 after buying an additional 44,180 shares during the period. Finally, Fuller & Thaler Asset Management Inc. acquired a new position in Lantheus during the first quarter valued at $17,813,000. 97.14% of the stock is owned by hedge funds and other institutional investors.
幾家對衝基金最近調整了對該股的持有量。先鋒集團(Vanguard Group Inc.)第一季度將其在蘭修斯的頭寸提高了32.9%。先鋒集團現在持有這家醫療設備供應商5,742,083股股票,價值317,595,000美元,在此期間又購買了1,422,269股。紐約梅隆銀行(Bank Of New York Mellon Corp)第一季度將其在Lantheus的頭寸提高了2.7%。紐約梅隆銀行(Bank Of New York Mellon Corp)目前持有這家醫療設備提供商629,033股股票,價值34,791,000美元,在此期間又購買了16,422股。景順股份有限公司在第一季度將其在Lantheus的持倉提高了1.3%。景順公司目前持有這家醫療設備供應商的522,633股股票,價值28,908,000美元,在此期間又購買了6,706股。嘉信理財(Charles Schwab Investment Management Inc.)第一季度將其在蘭修斯的持倉提高了9.2%。嘉信理財投資管理公司(Charles Schwab Investment Management Inc.)目前持有這家醫療設備提供商522,322股股票,價值28,890,000美元,在此期間又購買了44,180股。最後,Fuller&Thaler Asset Management Inc.在第一季度收購了蘭修斯的一個新頭寸,價值17,813,000美元。97.14%的股票由對衝基金和其他機構投資者持有。
About Lantheus
關於蘭修斯
(Get Rating)
(獲取評級)
Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors.
蘭修斯控股公司開發、製造和商業化診斷和治療產品,幫助世界各地的臨牀醫生診斷和治療心臟病、癌症和其他疾病。它提供了用於心臟超聲檢查的微氣泡超聲增強劑DEFINITY;用於核醫學的氚發生器TechneLite;用於評估肺功能的Xenon-133;用於確定大腦內因中風而血流受阻或減少的區域的Neurolite;可注射的Tc-99m標記顯像劑心臟;用於檢測心血管疾病的鉈-201;以及用於檢測各種感染和癌症腫瘤的鎵-67。
See Also
另請參閲
- Get a free copy of the StockNews.com research report on Lantheus (LNTH)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc's Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It's Cheap
- Why Apple Could Be At All-Time Highs By Year End
- 免費獲取StockNews.com關於蘭修斯的研究報告(LNTH)
- MarketBeat:回顧中的一週8/1-8/5
- 如何利用高貝塔係數股票最大化你的投資利潤
- 克羅諾斯集團(Cronos Group Inc.)營收上升,是時候收購了嗎?
- Beyond Meat不是沒有希望,而且它很便宜
- 蘋果為何可能在年底創下歷史新高
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.
接受蘭修斯日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Lantheus和相關公司的最新新聞和分析師評級的每日簡要摘要。